Royalty Pharma Q1 adjusted cash receipts $1,131M (+87% YoY); reaffirms FY guidance $2,850-2,950M

Royalty Pharma plc

2023-Q1 EPS reported $0.76 revenue$683,971,000

Adjusted Cash Receipts $1,131M, +87% YoY; underlying growth 11% ex-Zavzpret milestone and Biohaven payments.
GAAP net cash from ops $1,034M (+125% YoY) includes $475M Zavzpret milestone and $35M Airsupra payment.
Announced up to $1.6B in new royalty deals (Spinraza, pelacarsen, KarXT) and $1.0B share buyback program.
Reaffirmed FY23 Adjusted Cash Receipts guidance $2,850-2,950M (underlying growth 4-9% ex-milestones).
Portfolio milestones: FDA approvals for Zavzpret, Airsupra, Trodelvy; positive Xtandi Phase 3 data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Royalty Pharma plc updated its the quarter ended March 31, 2023 guidance (reaffirmed).

Period: the quarter ended March 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 9, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.